<DOC>
	<DOCNO>NCT00656630</DOCNO>
	<brief_summary>The purpose study develop validate human laboratory model prediction medication efficacy clinical trial relapse prevention alcohol dependence .</brief_summary>
	<brief_title>Medication Development Alcoholism : Acamprosate Versus Naltrexone</brief_title>
	<detailed_description>This double-blind , 3-cell , outpatient human laboratory study determine degree acamprosate naltrexone suppress subjective physiological responsivity alcohol cue relative placebo early abstinence .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Males female ≥ 18 ≤ 55 year age Meets Diagnostic Statistical ManualFourth Edition ( DSMIV ) criteria current alcohol dependence Does desire treatment Alcohol free , verified breath alcohol concentration , Clinical Institute Withdrawal Assessment ( CIWA ) ≤ 8 , time testing , evidence drinking least 3 day 7 day prior cue reactivity session Able complete understand questionnaire study procedure English Verbal I.Q . estimate ≥ 85 Signed inform consent Currently meet DSMIV criterion dependence substance alcohol nicotine Significant medical disorder increase potential risk interfere study participation Sexually active woman childbearing potential pregnant , nursing , refuse use reliable method birth control Meets DSMIV criterion major Axis I disorder , include depression anxiety disorder Treatment within month prior screen investigational medication may influence drink outcome , e.g. , disulfiram ( Antabuse ) , naltrexone ( ReVia ) , acamprosate ( Campral ) , antidepressant psychotropic agent Chronic treatment narcoticcontaining medication previous month evidence current opiate use Liver function test three time normal elevate bilirubin No fix domicile and/or availability telephone beeper Current involvement plan treatment prior study completion Patients history adverse drug reaction study drug ingredient Failure take doubleblind medication prescribe Inability understand comply provision protocol consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>